Scientific Advisory Board


 
 
     
 
 

Dr. Stephen Ansell

 
Dr. Ansell is a Professor of Medicine at the Mayo Clinic College of Medicine, as well as the Chair of the Mayo Clinic Lymphoma Group and Chair of the Faculty Development and Recruitment for Hematology. His clinical practice interests focus on non-Hodgkin lymphoma, Hodgkin’s disease, and Waldenstrom’s macroglobulinemia. His research focuses on the biology of these diseases and on developing new therapies. In addition, Dr. Ansell has served on the editorial boards of American Journal of Hematology, Journal of Clinical Oncology, Blood Cancer Journal and Clinical Lymphoma and Myeloma, and has co-authored more than 234 articles in peer-reviewed journals. Dr. Ansell received his medical degree and Ph.D. both at the University of Pretoria, South Africa.
 

Dr. Andreas Engert

 
Dr. Engert is a Professor of Internal Medicine, Hematology, and Oncology at the University Hospital of Cologne in Germany and Chairman of the German Hodgkin Study Group. Previously, he worked at the Imperial Cancer Research Fund and the Royal Free Hospital in London, United Kingdom, on new immunotherapeutic approaches for cancer. After returning to Cologne, his group focused on developing antibody-based immunotherapy for patients with malignant lymphoma resulting in a number of experimental phase I/II clinical trials. Additionally, Professor Engert has published more than 400 original papers in journals such as New England Journal of Medicine, Lancet, Nature Genetics, and Journal of Clinical Oncology. His numerous awards include the Ludwig-Heilmeyer-Medal, the Arthur-Pappenheim Award, the Research Award of the University of Cologne, the award of the German Cancer Society 2011 and the Paul-Martini-Prize 2013. Dr. Engert received his medical degree at the Hannover Medical School in Germany.
 

Dr. Owen O’Connor

 
Dr. O’Connor is a Professor of Medicine and Experimental Therapeutics, Director of the Center for Lymphoid Malignancies, and Co-Program Director of the Lymphoid Development and Malignancy Program in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center. After nearly a decade at Memorial Sloan Kettering Cancer Center, and a number of leadership positions at prestigious institutions in New York City, most recently he has assumed a position to create a new Center devoted to the Lymphoid Malignancies at Columbia University. This center is uniquely focused on the translational aspects of lymphoma research, bringing together a truly multidisciplinary approach to blood cancer research. He has become an internationally recognized authority on the management of Hodgkin lymphoma and non-Hodgkin lymphoma, and is unique in that he has both co-invented and developed many new drugs for these diseases. Dr. O’Connor attained his Ph.D. in Biochemistry and Toxicology from the New York University School of Medicine, and his M.D. from The University of Medicine and Dentistry of New Jersey.
 
 
 
 

Dr. Andrew M. Evens, DO, MSc, FACP

 
Dr. Evens is Professor of Medicine at Tufts University School of Medicine and he is Chief of the Division of Hematology/Oncology and Director of the Tufts Cancer Center at Tufts Medical Center in Boston, Massachusetts. He was also named the Chan Soon-Shiong Endowed Scholar in Precision Medicine at Tufts Medical Center. Dr. Evens completed his Hematology/Oncology fellowship at Northwestern University Feinberg School of Medicine and The Robert H. Lurie Comprehensive Cancer Center (RHLCCC) where he also remained on faculty for approximately 15 years. Before arriving to Tufts Medical Center, he was a faculty member at the University of Massachusetts Medical School and the UMass Memorial Cancer Center where he served as the Deputy Director for the Cancer Center. Dr. Evens’ focus is in the biology, prognosis, and treatment of Non-Hodgkin lymphoma and Hodgkin disease/lymphoma. He has designed and conducted a multitude of clinical trials in lymphoid malignancies and he has authored or co-authored more than 100 original articles in this field. Dr. Evens also maintains a R01-funded translational lymphoma laboratory examining lymphoma biology, signal transduction pathways, free radical-mediated biology, and the development of novel targeted agents for the treatment of lymphoma. Additionally, Dr. Evens is an Associate Editor for the British Journal of Haematology; he chairs the Hematology Panel for the VA R01 Scientific Merit Review committee; and he is a primary member of the Hodgkin Lymphoma Working Group for the NIH and NCI Steering Committee.
 
Dr. Michael Caligiuri
 
Dr. Caligiuri is a Director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital in Columbus, Ohio. His lab’s research focus includes the development and normal role of natural killer (NK) cells so as to exploit their properties to develop effective therapies against cancer and immune deficiency. Dr. Caligiuri’s lab largely focuses on the human system, but has mouse models of both acute leukemia and NK-cell development whereby he studies the pathogenesis of both acute myeloid leukemia and large granular lymphocyte leukemia in order to develop novel therapies to treat these diseases. He has designed and conducted many clinical studies for leukemia and lymphoma patients and has authored or co-authored more than 300 original articles on immunology and/or leukemia. Dr. Caligiuri is a member of the Board of Directors for the American Association of Cancer Research and currently the President of the Society of Natural Immunity.  He chairs the Institute of Medicine’s National Cancer Policy Forum and chairs or is a member of 12 cancer center advisory boards across the country. Dr. Caligiuri received his medical degree from Stanford University School of Medicine and completed his training in internal medicine, oncology and immunology at Harvard University.
 

Dr. Max Topp

 
Max S. Topp, MD, is an Associate Professor of Internal Medicine, Hematology, and Oncology. Between 1997 and 2001 he worked at the Fred Hutchinson Cancer Research Center, Seattle, USA, on adoptive immunotherapy for infectious disease and cancer. After returning to Tuebingen, his group focused on developing immunotherapy protocols for both infectious disease and cancer with the focus on B-cell malignancies. After transferring to University Hospital of Wuerzburg, he was appointed a consultant and became head of hematology in 2014. Professor Topp has published more than 55 original papers in journals such as Lancet Oncology, JCO, Blood and others. He pioneered the first immunotherapy drug for the treatment of acute leukemias. He received his medical degree at the Berlin Medical School in Germany and had his medical training at the Berlin Medical School and the University Hospital of Tuebingen (both in Germany).
 
 
 



 
  Impressum Disclaimer Data Privacy